Navigation Links
BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
Date:9/7/2015

NESS ZIONA, Israel, September 8, 2015 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Company's CEO, Dr. Ron Babecoff, will participate in the Rodman & Renshaw 17th Annual Global Investment Conference, taking place at the St. Regis hotel in New York from September 8-10, 2015.

BiondVax CEO, Dr. Ron Babecoff, is scheduled to present on Thursday, September 10, 2015 at 10:25am Eastern Time.  The corporate presentation which Dr. Babecoff will present at the conference is available for download from the investor relations section of BiondVax's website.

At the conference there will be an opportunity for investors to meet one-on-one with Dr. Ron Babecoff. In addition, Dr. Babecoff will be meeting investors and analysts throughout the week on a non-deal roadshow in both Boston and New York. Investors interested in meeting with management should contact the Investor Relations team at BiondVax at biondvax@gkir.com.

About BiondVax Pharmaceuticals Ltd 

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

For further information, please contact:

Company Contact
Limor Chen, Director of  BD
limor.c@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com


'/>"/>
SOURCE Biondvax Pharmaceuticals Ltd
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option
2. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
3. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
4. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
5. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
9. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
10. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
11. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... June 13, 2019 , ... Recent lawsuits, ... with a back problem, underscore the responsibility of employers to provide reasonable accommodations ... accommodation requests are reasonable and which are not - from requests by hearing-impaired ...
(Date:6/13/2019)... , ... June 13, 2019 , ... The American Psychiatric ... director to succeed current executive director Nicholas Croce Jr., MS. The search will be ... Board of Directors, past APNA Presidents, and Council and Chapter leaders. , The job ...
(Date:6/13/2019)... ... 2019 , ... Online laser therapy education portal, Laser Therapy ... about non-invasive photobiomodulation (PBM) therapy to relieve pain. LTU will host a live ... , Also known as low-level laser therapy (LLLT), PBM was first ...
Breaking Medicine Technology:
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... ... , has announced that the final entry deadline in the 2019 competition is ... , Recognized as the world’s premier business awards program, The IBAs attract nominations ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... RN, BSN, CRNI and Charles “Charlie” Schadewald as the newest members of its ... as members of NICA’s Advisory Committee. The NICA Advisory Committee is comprised of ...
(Date:6/13/2019)... ... June 13, 2019 , ... GlycoMark, Inc. announced a new ... Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for ... SGLT-2 inhibitors are used to lower glucose levels in patients with diabetes by ...
(Date:6/12/2019)... ... June 12, 2019 , ... GlucoseZone , ... pleased to announce that LaurieAnn Scher, MS, RD, CDE GlucoseZone’s Chief Strategy ... Diabetes Educator of the Year 2019, honoring best-in-class learning and development initiatives within ...
(Date:6/12/2019)... ... June 12, 2019 , ... Learn ... get valuable advice on innovative branding and network with others in this growing ... media representatives, farmers, nutritionists, manufacturers and others who are part of the rapidly ...
Breaking Medicine News(10 mins):